Analyst Price Targets — ZVRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 10, 2026 5:32 pm | Jason McCarthy | Maxim Group | $35.00 | $13.67 | TheFly | Zevra Therapeutics price target raised to $35 from $25 at Maxim |
| June 10, 2026 10:52 am | Eddie Hickman | Guggenheim | $29.00 | $13.66 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Guggenheim |
| June 9, 2026 10:50 am | Sumant Kulkarni | Canaccord Genuity | $29.00 | $12.09 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Canaccord |
| May 8, 2026 11:15 am | Eddie Hickman | Guggenheim | $25.00 | $11.00 | TheFly | Zevra Therapeutics price target raised to $25 from $23 at Guggenheim |
| March 10, 2026 10:40 am | Eddie Hickman | Guggenheim | $23.00 | $11.03 | StreetInsider | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim |
| December 30, 2025 11:38 am | Brandon Folkes | H.C. Wainwright | $26.00 | $8.82 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA) |
| November 6, 2025 2:04 pm | Kristen Kluska | Cantor Fitzgerald | $24.00 | $9.29 | TheFly | Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald |
| November 6, 2025 1:48 pm | — | Canaccord Genuity | $24.00 | $8.95 | TheFly | Zevra Therapeutics price target lowered to $24 from $25 at Canaccord |
| March 13, 2025 12:25 pm | — | Guggenheim | $22.00 | $7.94 | TheFly | Zevra Therapeutics price target raised to $22 from $20 at Guggenheim |
| March 12, 2025 9:42 am | — | JMP Securities | $18.00 | $7.92 | TheFly | Zevra Therapeutics price target raised to $18 from $17 at Citizens JMP |
Latest News for ZVRA
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer (“CMO”) Adrian Quartel, M.D., FFPM, will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Quartel will continue…
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that…
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursuant to the Company's…
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZVRA.
U.S. House Trading
No House trades found for ZVRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.